TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.
On November 14, 2025, Dr. Reddy’s Laboratories announced that the United States Food & Drug Administration (USFDA) completed a Good Manufacturing Practice (GMP) inspection at their API facility in Srikakulam, Andhra Pradesh, with zero observations. This successful inspection underscores the company’s commitment to maintaining high-quality standards in its manufacturing processes, potentially strengthening its position in the global pharmaceutical market.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a prominent Indian pharmaceutical company based in Hyderabad, Telangana. The company specializes in the production of generic medications, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products, with a significant focus on both domestic and international markets.
Average Trading Volume: 1,014,912
Technical Sentiment Signal: Hold
Current Market Cap: $11.71B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.